Celldex Therapeutics’ CDX-0159, an inhibitor of the KIT receptor, led to sustained reductions in plasma tryptase levels in the phase 1 trial.
Dupixent (dupilumab), developed by Regeneron and Sanofi, has shown “significant efficacy” for Eosinophilic Esophagitis in a phase 3 trial.
A recent study involving the Boston Birth Cohort associated concentrations of folic acid levels at birth with the development of food allergies during childhood.
Childhood food allergy diagnoses have been associated with the use of prescription antibiotics during the first year of life.
Subcutaneous allergen immunotherapy has been demonstrated to be a safe and effective treatment for individuals allergic to a common fungus.